Home  »  Companies   »  Analyst Oppenheimer Price Target And Rating For PO...

Analyst Oppenheimer Price Target And Rating For POINT Biopharma Global Inc. (PNT)

POINT Biopharma Global Inc. (NASDAQ:PNT) concluded the trading at $6.86 on Wednesday, November 23 with a fall of -0.58% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $6.90 and 5Y monthly beta was reading 0.09 with its price kept floating in the range of $6.5594 and $6.96 on the day. Considering stock’s 52-week price range provides that PNT hit a high price of $10.98 and saw its price falling to a low level of $4.25 during that period. Over a period of past 1-month, stock came subtracting -19.01% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

With its current market valuation of $688.95 million, POINT Biopharma Global Inc. is set to declare its quarterly results on Nov 10, 2022 – Nov 14, 2022. Analysts are in estimates of -$0.28 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.02 for 2022 with estimates of that growing to -$1.26 in next year. These estimates are suggesting current year growth of -64.50% for EPS and -23.50% growth next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review PNT stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Sell for it.

Digging deeper we become aware of the PEG ratio of the PNT stock which is currently positioned at 0. It further provides that stock’s current price level is -13.88% away from its 20-day simple moving average and is -14.67% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 42.59 while volatility remained at 5.86% over the past week which changes to 8.26% when measuring it over the past month. Average true range or ATR is currently at 0.62.

Having a second look at POINT Biopharma Global Inc. (NASDAQ:PNT) provides that stock’s average daily trading volume for 3 months was 929.98K, while it jumped to 1.78 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 92.40 million.

The percentage of outstanding shares held by the insiders is 2.90% while it is 57.80% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 7.17 million which implies a short ratio of 8.62. This shows down a 6.89% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 17.28 million in the previous month. Addition of 22.50% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]